by uimmodulon_admin | 17th September 2020 | archive
Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a...
by uimmodulon_admin | 4th August 2020 | archive
Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a...
by uimmodulon_admin | 3rd August 2020 | archive
Collaboration will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma Uxbridge, UK and Lisbon, Portugal – 3 August 2020 –...
by uimmodulon_admin | 27th July 2020 | archive
Additional investigator-initiated phase I/II study planned to investigate the safety and efficacy of IMM101 in limited metastatic pancreatic cancer; study could start by the end of 2020 Uxbridge, UK – 27 July 2020 – Immodulon, the immuno-oncology company, is pleased...
by uimmodulon_admin | 9th July 2020 | archive
Phase 3 study approved by Health Canada seeks to boost cancer patients’ immune systems with IMM-101 to protect against severe COVID-19 and other viral lung infections Uxbridge, UK – 9 July 2020 – Immodulon, the immuno-oncology company, is pleased to note that a...
by uimmodulon_admin | 28th May 2020 | archive
The phase I/II trial will recruit up to 42 participants with inoperable leiomyosarcoma or dedifferentiated liposarcoma Uxbridge, UK – 28 May 2020 – Immodulon, the immuno-oncology company, today announces that the Company has received confirmation from the US Food and...
by uimmodulon_admin | 17th April 2020 | archive
Dr. Habita brings deep expertise in clinical drug development, as the Company continues to seek to progress its uniquely differentiated clinical programmes in immuno-oncology Uxbridge, UK – 14 April 2020 – Immodulon, the immuno-oncology company, announces the...
by uimmodulon_admin | 12th March 2020 | archive
Claims cover methods of treating pancreatic cancer or melanoma with IMM-101 in combination with anti-PD-L1, anti-PD1 or anti-CLTA4 antibodies New patents expected to expire in 2034 Immodulon’s IMM-101 is currently in a phase II clinical trial in combination with...
by uimmodulon_admin | 16th December 2019 | archive
Poster presentation at CICON and oral and poster presentation at BSI demonstrated the immunomodulatory effects of IMM-101 in pre-clinical models Oral and poster presentation at Pancreatic Cancer Symposium reported results from the IMAGE 1 open label Phase II study in...
by uimmodulon_admin | 21st November 2019 | archive
Positive results from phase 1 follow up study supports current phase 2 clinical trial of IMM-101 in combination with checkpoint inhibitor therapy Immodulon, the immuno-oncology company, today announces that long-term survival data from its phase 1 study in 18 patients...